No ano passado, Organon & Co gerou US$ 1.75B em seu segmento de melhor desempenho, Women’s Health. A região Europe and Canada teve a maior contribuição, com US$ 1.62B no período. No último trimestre, Organon & Co registrou receita de US$ 419.00M no período encerrado em 2026-06-30, proveniente principalmente do segmento Women’s Health. A região Europe and Canada teve a maior contribuição, com receita de US$ 432.00M.

Por Empresa

Receita

Proporção

Anual

Anual

Trimestral

Women’s Health

Cardiovascular

Non-Opioid Pain, Bone and Dermatology

Respiratory

Other

Biosimilars

Other Organon Products segment

Supply sales to Merck affiliates

Other Merck Retained Products segment

Keytruda

Januvia/Janumet

Simponi

Zostavax

Gardasi/Gardasil

Varivax

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

Women’s Health

1.75B(28.19%)

1.78B(27.75%)

1.70B(27.18%)

1.67B(27.10%)

1.61B(25.57%)

1.55B(23.79%)

2.26B(29.09%)

2.10B(21.52%)

1.99B(18.96%)

Cardiovascular

1.14B(18.26%)

1.32B(20.66%)

1.46B(23.31%)

1.50B(24.25%)

1.62B(25.63%)

1.87B(28.67%)

2.07B(26.66%)

2.33B(23.88%)

3.01B(28.70%)

Non-Opioid Pain, Bone and Dermatology

987.00M(15.88%)

867.00M(13.54%)

782.00M(12.49%)

788.00M(12.76%)

830.00M(13.17%)

834.00M(12.77%)

884.00M(11.37%)

737.00M(7.54%)

810.00M(7.71%)

Respiratory

842.00M(13.55%)

1.02B(15.90%)

1.06B(16.99%)

1.04B(16.80%)

1.01B(16.02%)

1.15B(17.62%)

1.47B(18.90%)

1.58B(16.15%)

1.72B(16.41%)

Other

809.00M(13.01%)

756.00M(11.81%)

662.00M(10.57%)

698.00M(11.31%)

611.00M(9.69%)

683.00M(10.46%)

734.00M(9.44%)

550.00M(5.63%)

573.00M(5.46%)

Biosimilars

691.00M(11.12%)

662.00M(10.34%)

593.00M(9.47%)

481.00M(7.79%)

423.00M(6.71%)

331.00M(5.07%)

251.00M(3.23%)

63.00M(0.64%)

5.00M(0.05%)

Other Organon Products segment

--(--)

202.00M(3.20%)

106.00M(1.62%)

103.00M(1.32%)

924.00M(9.45%)

1.08B(10.32%)

Supply sales to Merck affiliates

--(--)

432.00M(4.42%)

392.00M(3.73%)

Other Merck Retained Products segment

--(--)

381.00M(3.90%)

462.00M(4.40%)

Keytruda

--(--)

309.00M(3.16%)

165.00M(1.57%)

Januvia/Janumet

--(--)

113.00M(1.16%)

91.00M(0.87%)

Simponi

--(--)

92.00M(0.94%)

94.00M(0.90%)

Zostavax

--(--)

76.00M(0.78%)

31.00M(0.30%)

Gardasi/Gardasil

--(--)

63.00M(0.64%)

5.00M(0.05%)

Varivax

--(--)

19.00M(0.19%)

61.00M(0.58%)

Por Região

Receita

Proporção

Anual

Anual

Trimestral

Europe and Canada

United States

Latin America, Middle East, Russia and Africa

Asia Pacific and Japan

China

Other

Europe, Middle East and Africa

Japan

Other Asia Pacific

Latin America

Canada

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

Europe and Canada

1.62B(26.03%)

1.76B(27.53%)

1.67B(26.71%)

1.63B(26.42%)

1.74B(27.62%)

1.73B(26.42%)

1.89B(24.34%)

--(--)

United States

1.60B(25.80%)

1.57B(24.55%)

1.48B(23.60%)

1.44B(23.28%)

1.38B(21.94%)

1.41B(21.56%)

2.02B(25.99%)

2.00B(20.41%)

2.46B(23.47%)

Latin America, Middle East, Russia and Africa

1.07B(17.25%)

1.03B(16.15%)

965.00M(15.41%)

895.00M(14.50%)

841.00M(13.34%)

857.00M(13.12%)

923.00M(11.87%)

--(--)

Asia Pacific and Japan

1.00B(16.09%)

1.05B(16.40%)

1.13B(18.03%)

1.14B(18.51%)

1.17B(18.61%)

1.53B(23.50%)

1.79B(23.00%)

--(--)

China

829.00M(13.34%)

847.00M(13.23%)

864.00M(13.80%)

917.00M(14.85%)

933.00M(14.80%)

873.00M(13.36%)

1.03B(13.21%)

908.00M(9.29%)

830.00M(7.90%)

Other

93.00M(1.50%)

137.00M(2.14%)

154.00M(2.46%)

151.00M(2.45%)

233.00M(3.70%)

133.00M(2.04%)

124.00M(1.59%)

-39.00M(-0.40%)

63.00M(0.60%)

Europe, Middle East and Africa

--(--)

3.74B(38.23%)

3.90B(37.11%)

Japan

--(--)

1.12B(11.46%)

1.17B(11.14%)

Other Asia Pacific

--(--)

943.00M(9.65%)

966.00M(9.20%)

Latin America

--(--)

937.00M(9.58%)

915.00M(8.71%)

Canada

--(--)

175.00M(1.79%)

195.00M(1.86%)